We caught up with Davinder Ramsingh, MD, to talk about the potential of using low-intensity focused ultrasound (LIFU) to open the blood–brain barrier.
- Beyond GalNAc: Reengineering siRNA For Extrahepatic Delivery
- Engineering CAR T Cells With mRNA-LNPs: Applying Oncology Learnings To Allergic Diseases
- The Future Of Cancer Drug Discovery Is Targeted Immune Activation
- Part 4 cGMP Summaries For Combination Products: Uncovering FDA Expectations
- Unpacking The FDA Draft Guidance On Container Closure Systems
- Turning A Historically Limited Modality Into A Respiratory Drug Opportunity
- Why Delivery Is Defining The Next Era Of Neuromuscular Therapeutics
- Inquiries In Inhalation, Part 2: Having A Nose For Innovation
ON-DEMAND WEBINARS
Strengthen risk mitigation strategies while ensuring regulatory alignment. Gain valuable insights into best practices and proactive approaches for building a robust and future-ready CCS.
Using volatile processing aids to increase drug solubility in more environmentally friendly solvents, like methanol, reduces the amount of solvent required to manufacture amorphous solid dispersions (ASDs).
Explore how adaptable technologies and strategic partnerships help navigate Annex 1 compliance and technical hurdles to ensure the successful delivery of complex drug products.
Explore 3D screen printing’s potential to revolutionize pharmaceutical manufacturing with scalable, customizable, multi-drug tablets and precise, patient-centric drug release profiles.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-1310024666-genetic-digital-dna]( "How Nanoparticle Platforms Are Unlocking Genetic Medicine's Potential")
How Nanoparticle Platforms Are Unlocking Genetic Medicine's PotentialExplore how the HIT SCAN platform accelerates gene therapy delivery by screening polymeric nanoparticles, enhancing precision and regulatory pathways for next-generation genetic medicines.
-
![West Pharma - Article 2 - ELAS LYO Lyotec-012 LREZ]( "Have You Selected The Right Stopper For Your Lyophilized Drug Product?")
Have You Selected The Right Stopper For Your Lyophilized Drug Product?Component selection is a complex process. Packaging considerations should occur concurrent with drug development to mitigate risk at every step of the drug development process.
-
![Reducing Costs And Improving Adherence For Self-Administration Of New Biologics]( "Reduce Costs And Improve Adherence For Self-Administration Of Biologics")
Reduce Costs And Improve Adherence For Self-Administration Of BiologicsThere is a growing trend toward wearable injectors for bolus delivery in order to help improve adherence and lower the costs of therapy.
-
![nanoparticles-drug molecule-GettyImages-1428647836]( "Accelerate LNP Manufacturing With Automated Process Development")
Accelerate LNP Manufacturing With Automated Process DevelopmentManual LNP formulation introduces process variability that threatens particle quality and yield. As programs scale toward clinical production, maintaining strict control over CQAs becomes essential.
-
![drug delivery trends]( "Trends In Drug Delivery: The Growth Of Cartridge Based Technology")
Trends In Drug Delivery: The Growth Of Cartridge Based TechnologyAs pharma companies evaluate the delivery systems for their drug product, there are several reasons why they may select a cartridge-based system compared to a pre-filled syringe or vial.
-
![GettyImages-525062561-syringe-vaccine-injection-subcutaneous]( "Considerations In Formulation Development Of Injectable Solutions")
Considerations In Formulation Development Of Injectable SolutionsInjectable solutions offer an alternative to oral dosage form due to fast onset, reproducible PK/efficacy profile, high bioavailability, and suitability of administration under hospital setting.
-
![GettyImages-1481197683 water molecules]( "What is Hot Melt Extrusion, And How Can It Benefit Your Drug Product?")
What is Hot Melt Extrusion, And How Can It Benefit Your Drug Product?Poor API solubility delays pipelines. Discover how hot-melt extrusion creates amorphous solid dispersions to break down crystal lattices and boost bioavailability via solvent-free manufacturing.
-
![GettyImages-1346675635-lab-tablet-research-team]( "Simultaneous Spray Drying For Innovative Dry Powder Inhaler Combination Formulations")
Simultaneous Spray Drying For Innovative Dry Powder Inhaler Combination FormulationsDr. Kimberly Shepard, a principal R&D engineer at Lonza, offered insights on recent innovations pioneered in spray drying. Shepard also discussed spray drying technologies capable of combining small-molecule APIs with biotherapeutic molecules.
-
![Syringes GettyImages-171324030]( "Stainless Steel Needles: Quantifying Cobalt Risk For EU Regulation")
Stainless Steel Needles: Quantifying Cobalt Risk For EU RegulationLearn how a partner who is committed to ensuring the safety of medical devices by mitigating the risk of chemical interaction with drugs is crucial for navigating the regulatory pathway to approval.
-
![Multicolored pills-GettyImages-1370358685]( "Solid Form Strategies For Increasing Oral Bioavailability")
Solid Form Strategies For Increasing Oral BioavailabilityOptimizing a drug’s solid form can improve its solubility and bioavailability when further molecular modifications are prohibitive.
TOM'S TAKES ON DRUG DELIVERY
TALKING WITH TOM VIDEOCASTS
Fran offers keen industry and technical insights exclusively on Drug Delivery Leader.
DELIVERED BY DEGRAZIO
-
![Delivered _by _DeGrazio_Logo_Color_2]( "Unpacking The FDA Draft Guidance On Container Closure Systems")
Unpacking The FDA Draft Guidance On Container Closure SystemsIn this article, Fran DeGrazio reflects on the significance of the FDA Draft Guidance on Container Closure Systems, the first update since 1999. DeGrazio places the CCS draft guidance in the current context of science-based and risk-based product development for combination products and other injectable drug product delivery systems. She also addresses the integration of CCS guidance into the development organization’s QMS (Quality Management System).
FREE EBOOK
Why Human Factors Are Critical To Drug Delivery Device Success
In today’s highly competitive biopharma market, successful therapies prioritize the patient experience. Increasingly, patients expect to receive advanced therapies at home or in decentralized care settings, which require delivery methods that are easy to use and comfortable.
This collection explores how drug delivery teams can incorporate patient-centricity across development, from early human factors strategies to modality selection, ensuring safe, effective therapies that translate to real-world care.
